Investigational drug · Phase 2
XY03-EA
Also called: per dose
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Stroke, Ischemic.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
2
Any phase or sponsor naming "XY03-EA"
First trial start
2024
Dec 15, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "XY03-EA", any sponsor or status.
Conditions studied
As listed on its trial records.
- Stroke, Ischemic
Approved drugs for the same conditions: Stroke prevention · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "XY03-EA" as an intervention, largest first.
- A Study of XY03-EA Tablets in the Treatment of Acute Ischemic StrokePivotal-lookingStatus unknown
Shijiazhuang Yiling Pharmaceutical Co. LtdIndustry
NCT05515393 · 420 participants (planned) · Start Sep 24, 2022 · Primary completion Dec 30, 2023
Drug: XY03-EA; XY03-EA Placebo · For: Acute Ischemic Stroke
Sites: Shijiazhuang, China
- A Phase Ⅱb Study of XY03-EA Tablets in Acute Ischemic StrokePivotal-lookingCompleted
Shijiazhuang Yiling Pharmaceutical Co. LtdIndustry
NCT06755944 · 360 participants · Start Dec 15, 2024 · Primary completion Jun 9, 2025
Drug: XY03-EA 150 mg (per dose); XY03-EA 300 mg (Regimen A) and 3 more · For: Stroke, Ischemic
Sites: Shijiazhuang, China
Newest research
PubMed records naming it or its code names, newest first.
- Cost-effectiveness of universal infant hepatitis B vaccination programme in Finland.
Nieminen T, Nurhonen M, Leino T, et al. · Vaccine 2026
- Nonclinical safety profile for DCR-AUD GalNAc-conjugated siRNA: Subchronic versus chronic findings in mouse and non-human primate.
Sanftner L, Beaudry A, Kovalenko P, et al. · Regul Toxicol Pharmacol 2026
- Economic implications of switching to the hexavalent infant vaccine in an immunization program in India.
Kumar P, Singh K, Ray A, et al. · Hum Vaccin Immunother 2026
- Adherence and efficacy of the 0ߙ-ߙ7ߙ-ߙ21-day versus the 0ߙ-ߙ1ߙ-ߙ6-month hepatitis B vaccination schedules among people who use drugs: a two-year randomized controlled trial.
Hou X, Li N, Zhang H, et al. · Expert Rev Vaccines 2026
- Cost-effectiveness analysis of hepatitis E screening and vaccination: targeting vulnerable populations in outbreak and sporadic settings in China.
Liu H, Chen G, Jie Y, et al. · Emerg Microbes Infect 2026
- Effect of intrapartum hyoscine butylbromide and sodium bicarbonate on spontaneous vaginal birth in nulliparous women after induction of labour (SAINT): multicentre randomised placebo controlled factorial trial.
Michelsen TM, Leeves LT, Solhoff AV, et al. · BMJ 2026
Also in development for Stroke, Ischemic
- MLC1501Phase 32 trials
Moleac Pte Ltd. · Stroke, Stroke, Ischemic, Strokes Thrombotic
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.